RhumbLine Advisers
KYTX icon

RhumbLine Advisers’s Kyverna Therapeutics KYTX Stock Holding History

RhumbLine Advisers’s Portfolio KYTX Stock Details KYTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-31,614
Closed -$61K – 4283
2025
Q1 		$61K Buy
31,614
+5,694
+22% +$16.8K ﹤0.01% 3532
2024
Q4 		$96.9K Buy
25,920
+6,153
+31% +$29.5K ﹤0.01% 3482
2024
Q3 		$96.7K Sell
19,767
-240
-1% -$1.85K ﹤0.01% 3508
2024
Q2 		$150K Buy
+20,007
New +$306K ﹤0.01% 3378

Other funds holding KYTX

VVA
Vida Ventures Advisors Boston, Massachusetts $29.4M AUM 93.58% 1-Year Est. Return
GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IHG
Insight Holdings Group New York $1.42B AUM 41.03% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
MPM
MBB Public Markets Chicago, Illinois $839M AUM 20.48% 1-Year Est. Return
CCM
Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RhumbLine Advisers's KYTX Position: Q2 2025 in Review

RhumbLine Advisers sold out of Kyverna Therapeutics (KYTX) in Q2 2025, closing a stake of 31,614 shares — an estimated $61K sold.

RhumbLine Advisers first reported a position in KYTX in Q2 2024 and held it in 4 quarters. The position peaked at $150K in Q2 2024. 79 funds tracked by Wall St. Rank hold KYTX as of Q2 2025.

  • RhumbLine Advisers reported no remaining Kyverna Therapeutics position as of Q2 2025 after selling out during the quarter.
  • RhumbLine Advisers sold 31,614 Kyverna Therapeutics shares in Q2 2025, an estimated $61K.
  • RhumbLine Advisers first reported a position in Kyverna Therapeutics in Q2 2024 and held it in 4 quarters.
  • RhumbLine Advisers's Kyverna Therapeutics position peaked at $150K in Q2 2024.
  • 79 funds tracked by Wall St. Rank held Kyverna Therapeutics as of Q2 2025.

Based on RhumbLine Advisers's 13F filing for Q2 2025, filed 12 Aug 2025.